@inbook{dcb152e1da834fb180afec787da2a70f,
title = "Radiotracer and Microscopic Assessment of Vascular Function in Cancer Therapy",
abstract = "Vascular disrupting cancer therapy is aimed at causing a rapid shut-down of the established tumour blood supply, sufficient to induce secondary tumour cell death. It is conceptually distinct from anti-angiogenic therapy, which aims to prevent neo-vascularization of solid tumours. Several low molecular weight drugs have recently entered clinical trial as vascular disrupting agents or VDAs. The lead compound is the tubulin-binding, microtubule depolymerising agent, disodium combretastatin A4 3-O-phosphate (CA-4-P). Tissue blood flow rate (F) is a critical parameter for assessing functional efficiency of a blood vessel network following VDA treatment. CA-4-P causes almost complete cessation of blood flow in many tumour models within I hour of a moderate single dose of CA-4-P. Significant tumour blood flow shut-down has also been observed in clinical trials, without vascular damage in normal tissues. However, reasons for tumour selectivity of VDAs such as CA-4-P remain unclear. Here, we describe methods for evaluating vascular effects of VDAs in pre-clinical models of cancer and the current status of VDA treatments.",
keywords = "cancer therapy, vascular disruption, blood flow rate, intravital microscopy, combretastatin, combretastatin A-4, blood-flow, tumor, agent, phosphate",
author = "Tozer, {G. M.} and Cunningham, {Vincent Joseph}",
year = "2007",
doi = "10.1007/978-3-540-73044-6_117",
language = "English",
isbn = "9783540730439",
volume = "16",
series = "IFMBE Proceedings",
publisher = "Springer ",
pages = "457--460",
editor = "Tomaz Jarm and Peter Kramar and Anze Zupanic",
booktitle = "11th Mediterranean Conference on Medical and Biomedical Engineering and Computing 2007",
note = "MEDICON ; Conference date: 26-06-2007 Through 30-06-2007",
}